Topics

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Psoriasis,Arthritis, Psoriatic,Crohn Disease, Date of authorisation: 15/01/2009, Revision: 29, Status: Authorised

06:30 EDT 3 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Psoriasis,Arthritis, Psoriatic,Crohn Disease, Date of authorisation: 15/01/2009, Revision: 29, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Psoriasis,Arthritis, Psoriatic,Crohn Disease, Date of authorisation: 15/01/2009, Revision: 29, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Psoriasis,Arthritis, Psoriatic,Crohn Disease, Date of authorisation: 15/01/2009, Revision: 29, Status: Authorised"

Quick Search

Relevant Topics

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Arthritis
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...